Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2003;108:1707-1712
Published online before print September 22, 2003, doi: 10.1161/01.CIR.0000094734.67990.99
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
108/14/1707    most recent
01.CIR.0000094734.67990.99v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zisman, L. S.
Right arrow Articles by Canver, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zisman, L. S.
Right arrow Articles by Canver, C. C.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Heart Failure
Related Collections
Right arrow Cardio-renal physiology/pathophysiology
Right arrow Other heart failure
Right arrow Hypertrophy
Right arrow Myocardial cardiomyopathy disease
Right arrow Pulmonary circulation and disease
Right arrow ACE/Angiotension receptors
Right arrow Heart failure - basic studies

(Circulation. 2003;108:1707.)
© 2003 American Heart Association, Inc.


Clinical Investigations

Increased Angiotensin-(1-7)–Forming Activity in Failing Human Heart Ventricles

Evidence for Upregulation of the Angiotensin-Converting Enzyme Homologue ACE2

Lawrence S. Zisman, MD; Rebecca S. Keller, PhD; Barbara Weaver, MS; Qishan Lin, PhD; Robert Speth, PhD; Michael R. Bristow, MD, PhD; Charles C. Canver, MD

From The Heart Institute and The Center for Cardiovascular Sciences, Albany Medical Center, Albany, NY (L.S.Z., R.S.K., B.W., Q.L., C.C.C.); Washington State University, Pullman, Wash (R.S.); The University of Colorado Health Sciences Center, Denver (M.R.B.); and Myomatrix Therapeutics, Rensselaer, NY (L.S.Z., Q.L.).

Correspondence to Lawrence S. Zisman, MD, FACC, The Heart Institute, MC 55, Albany Medical College, 47 New Scotland Ave, Albany, NY 12208. E-mail zismanl{at}mail.amc.edu

Received January 7, 2003; revision received May 13, 2003; accepted May 13, 2003.

Abstract

Background— The formation of angiotensin-(1-7) from either angiotensin (Ang) I or Ang II in failing human hearts is not well understood.

Methods and Results— Angiotensinase activity in left and right ventricular membranes from 14 idiopathic dilated cardiomyopathy (IDC), 8 primary pulmonary hypertension (PPH), and 13 nonfailing human hearts was measured with either 125I-Ang I or 125I-Ang II as substrate. Ang-(1-7)–forming activity from 125I-Ang I was inhibited by thiorphan. With 125I-Ang II as substrate, Ang-(1-7) formation was inhibited by the ACE2-specific inhibitor C16. Western blotting with an anti-ACE2 antibody confirmed the presence of ACE2. Angiotensinase activity with 125I-Ang I as substrate was increased in failing IDC left ventricles (LVs) compared with nonfailing LVs (P<0.001). Ang-(1-7)–forming activity with 125I-Ang II as substrate was increased in both failing LVs and right ventricles (RVs) of IDC hearts and only in failing RVs of PPH hearts (PPH LV, 51.12±5.25; PPH RV, 89.97±11.21; IDC LV, 139.7±21.96; and IDC RV, 192.7±5.43; NF LV, 32.89±5.38; NF RV 40.49±10.66 fmol/min per milligram (P<0.05 PPH RV versus PPH LV; P<0.05 PPH RV versus NF RV; P<0.001 IDC LV versus NF LV; P<0.001 IDC RV versus NF RV).

Conclusions— Ang-(1-7)–forming activity from both Ang I and Ang II was increased in failing human heart ventricles but was mediated by at least two different angiotensinases. The first, which demonstrated substrate preference for Ang I, was neutral endopeptidase (NEP)-like. The second was ACE2, as demonstrated by Western blotting and inhibition of activity with C16.


Key Words: angiotensin • enzymes • cardiomyopathy




This article has been cited by other articles:


Home page
Exp PhysiolHome page
J. L. Guy, D. W. Lambert, A. J. Turner, and K. E. Porter
Functional angiotensin-converting enzyme 2 is expressed in human cardiac myofibroblasts
Exp Physiol, May 1, 2008; 93(5): 579 - 588.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
P. J. Garabelli, J. G. Modrall, J. M. Penninger, C. M. Ferrario, and M. C. Chappell
Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart
Exp Physiol, May 1, 2008; 93(5): 613 - 621.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. A. Hernandez Prada, A. J. Ferreira, M. J. Katovich, V. Shenoy, Y. Qi, R. A.S. Santos, R. K. Castellano, A. J. Lampkins, V. Gubala, D. A. Ostrov, et al.
Structure-Based Identification of Small-Molecule Angiotensin-Converting Enzyme 2 Activators as Novel Antihypertensive Agents
Hypertension, May 1, 2008; 51(5): 1312 - 1317.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
I. H. Zucker
Angiotensin-Converting Enzyme 2: A New Player in Central Sympathetic Regulation?
Circ. Res., March 28, 2008; 102(6): 628 - 629.
[Full Text] [PDF]


Home page
HypertensionHome page
S. Der Sarkissian, J. L. Grobe, L. Yuan, D. R. Narielwala, G. A. Walter, M. J. Katovich, and M. K. Raizada
Cardiac Overexpression of Angiotensin Converting Enzyme 2 Protects the Heart From Ischemia-Induced Pathophysiology
Hypertension, March 1, 2008; 51(3): 712 - 718.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
S. G. Haworth
The cell and molecular biology of right ventricular dysfunction in pulmonary hypertension
Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H10 - H16.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
P. deS. Senanayake, J. Drazba, K. Shadrach, A. Milsted, E. Rungger-Brandle, K. Nishiyama, S.-I. Miura, S. Karnik, J. E. Sears, and J. G. Hollyfield
Angiotensin II and Its Receptor Subtypes in the Human Retina
Invest. Ophthalmol. Vis. Sci., July 1, 2007; 48(7): 3301 - 3311.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. J. Trask, D. B. Averill, D. Ganten, M. C. Chappell, and C. M. Ferrario
Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats
Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H3019 - H3024.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. Wakahara, T. Konoshita, S. Mizuno, M. Motomura, C. Aoyama, Y. Makino, N. Kato, I. Koni, and I. Miyamori
Synergistic Expression of Angiotensin-Converting Enzyme (ACE) and ACE2 in Human Renal Tissue and Confounding Effects of Hypertension on the ACE to ACE2 Ratio
Endocrinology, May 1, 2007; 148(5): 2453 - 2457.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Keidar, M. Kaplan, and A. Gamliel-Lazarovich
ACE2 of the heart: From angiotensin I to angiotensin (1-7)
Cardiovasc Res, February 1, 2007; 73(3): 463 - 469.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
C. Diez-Freire, J. Vazquez, M. F. Correa de Adjounian, M. F. R. Ferrari, L. Yuan, X. Silver, R. Torres, and M. K. Raizada
ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR
Physiol Genomics, January 12, 2007; 27(1): 12 - 19.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. A.S. Santos, C. H. Castro, E. Gava, S. V.B. Pinheiro, A. P. Almeida, R. D. de Paula, J. S. Cruz, A. S. Ramos, K. T. Rosa, M. C. Irigoyen, et al.
Impairment of In Vitro and In Vivo Heart Function in Angiotensin-(1-7) Receptor Mas Knockout Mice
Hypertension, May 1, 2006; 47(5): 996 - 1002.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
K. Yamamoto, M. Ohishi, T. Katsuya, N. Ito, M. Ikushima, M. Kaibe, Y. Tatara, A. Shiota, S. Sugano, S. Takeda, et al.
Deletion of Angiotensin-Converting Enzyme 2 Accelerates Pressure Overload-Induced Cardiac Dysfunction by Increasing Local Angiotensin II
Hypertension, April 1, 2006; 47(4): 718 - 726.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
U. Danilczyk and J. M. Penninger
Angiotensin-Converting Enzyme II in the Heart and the Kidney
Circ. Res., March 3, 2006; 98(4): 463 - 471.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. M. Ferrario, A. J. Trask, and J. A. Jessup
Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function
Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2281 - H2290.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Iwata, R. T. Cowling, D. Gurantz, C. Moore, S. Zhang, J. X.-J. Yuan, and B. H. Greenberg
Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects
Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2356 - H2363.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. J. Warner, R. A. Lew, A. I. Smith, D. W. Lambert, N. M. Hooper, and A. J. Turner
Angiotensin-converting Enzyme 2 (ACE2), But Not ACE, Is Preferentially Localized to the Apical Surface of Polarized Kidney Cells
J. Biol. Chem., November 25, 2005; 280(47): 39353 - 39362.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. Karram, A. Abbasi, S. Keidar, E. Golomb, I. Hochberg, J. Winaver, A. Hoffman, and Z. Abassi
Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure
Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1351 - H1358.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
E. A. Tallant, C. M. Ferrario, and P. E. Gallagher
Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor
Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1560 - H1566.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. W. Lambert, M. Yarski, F. J. Warner, P. Thornhill, E. T. Parkin, A. I. Smith, N. M. Hooper, and A. J. Turner
Tumor Necrosis Factor-{alpha} Convertase (ADAM17) Mediates Regulated Ectodomain Shedding of the Severe-acute Respiratory Syndrome-Coronavirus (SARS-CoV) Receptor, Angiotensin-converting Enzyme-2 (ACE2)
J. Biol. Chem., August 26, 2005; 280(34): 30113 - 30119.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
L. S. Zisman
Myocardial infarction increases ACE2 expression in rat and humans: reply
Eur. Heart J., June 1, 2005; 26(11): 1141 - 1142.
[Full Text] [PDF]


Home page
CirculationHome page
C. M. Ferrario, J. Jessup, M. C. Chappell, D. B. Averill, K. B. Brosnihan, E. A. Tallant, D. I. Diz, and P. E. Gallagher
Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2
Circulation, May 24, 2005; 111(20): 2605 - 2610.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
M. J. Katovich, J. L. Grobe, M. Huentelman, and M. K. Raizada
Angiotensin-converting enzyme 2 as a novel target for gene therapy for hypertension
Exp Physiol, May 1, 2005; 90(3): 299 - 305.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
L. M. Burrell, J. Risvanis, E. Kubota, R. G. Dean, P. S. MacDonald, S. Lu, C. Tikellis, S. L. Grant, R. A. Lew, A. I. Smith, et al.
Myocardial infarction increases ACE2 expression in rat and humans
Eur. Heart J., February 2, 2005; 26(4): 369 - 375.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
L. S. Zisman
ACE and ACE2: a tale of two enzymes
Eur. Heart J., February 2, 2005; 26(4): 322 - 324.
[Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
N. Li, J. Zimpelmann, K. Cheng, J. A. Wilkins, and K. D. Burns
The role of angiotensin converting enzyme 2 in the generation of angiotensin 1-7 by rat proximal tubules
Am J Physiol Renal Physiol, February 1, 2005; 288(2): F353 - F362.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J.-C. Zhong, D.-Y. Huang, Y.-M. Yang, Y.-F. Li, G.-F. Liu, X.-H. Song, and K. Du
Upregulation of Angiotensin-Converting Enzyme 2 by All-trans Retinoic Acid in Spontaneously Hypertensive Rats
Hypertension, December 1, 2004; 44(6): 907 - 912.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. J. Huentelman, J. Zubcevic, J. A. Hernandez Prada, X. Xiao, D. S. Dimitrov, M. K. Raizada, and D. A. Ostrov
Structure-Based Discovery of a Novel Angiotensin-Converting Enzyme 2 Inhibitor
Hypertension, December 1, 2004; 44(6): 903 - 906.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
G. C. Douglas, M. K. O'Bryan, M. P. Hedger, D. K. L. Lee, M. A. Yarski, A. I. Smith, and R. A. Lew
The Novel Angiotensin-Converting Enzyme (ACE) Homolog, ACE2, Is Selectively Expressed by Adult Leydig Cells of the Testis
Endocrinology, October 1, 2004; 145(10): 4703 - 4711.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. S. Zisman, G. E. Meixell, M. R. Bristow, and C. C. Canver
Angiotensin-(1-7) Formation in the Intact Human Heart: In Vivo Dependence on Angiotensin II as Substrate
Circulation, October 7, 2003; 108(14): 1679 - 1681.
[Abstract] [Full Text] [PDF]